7xm app login for android

Former Tulane quarterback Darian Mensah has already found a new program in Duke, while Mississippi State's Michael Van Buren Jr., Wisconsin's Braedyn Locke and Cal's Fernando Mendoza are exploring changes of their own in the transfer portal. Mensah, a redshirt freshman with three years of eligibility remaining, told ESPN on Wednesday he has transferred to Duke. He attended the Blue Devils men's basketball game against Incarnate Word on Tuesday night. The Blue Devils (9-3) will face Mississippi in the Gator Bowl, but without 2024 starting quarterback Maalik Murphy and backup Grayson Loftis, who also entered the portal. Mensah, viewed as one of the top players in the portal, threw for 2,723 yards and 22 touchdowns and completed 65.9% of his passes. He led the Green Wave to a 9-4 record and the American Athletic Conference championship game, where they lost 35-14 to Army. Tulane will play Florida in the Gasparilla Bowl on Sunday. Van Buren, Mendoza and Locke announced on social media they had entered the portal. Van Buren started eight games as a true freshmen for the Bulldogs. He threw for 1,886 yards on 55% passing with 16 total touchdowns and seven interceptions for the Bulldogs (2-10, 0-8 Southeastern Conference). He took over as the starter when Blake Shapen suffered a season-ending shoulder injury in a 45-28 loss to Florida on Sept. 21. Shapen has said he plans to return next season. Van Buren, a 6-foot-1, 200-pound passer from St. Frances Academy in Maryland, had two 300-yard performances for the Bulldogs, including 306 yards and three touchdown passes in a 41-31 road loss against Georgia. Mendoza threw for 3,004 yards in 2024 with 16 TDs, six interceptions and a 68.7 completion percentage. "For the sake of my football future this is the decision I have reached," he posted. Locke passed for 1,936 yards with 13 touchdowns and 10 interceptions for Wisconsin this season. He said he will have two years of eligibility remaining at his next school. ANN ARBOR, Mich. — Michigan cornerback Will Johnson has joined defensive tackle Mason Graham in the NFL draft. Johnson declared for the draft on Wednesday, one day after Graham decided he would also skip his senior season with the Wolverines. Both preseason All-America players are expected to be first-round picks. Johnson was limited to six games this year due to an injury. He had two interceptions, returning them both for touchdowns to set a school record with three scores off interceptions. Johnson picked off nine passes in three seasons. Graham played in all 12 games this season, finishing with 3 1/2 sacks and seven tackles for losses. He had 18 tackles for losses, including nine sacks, in his three-year career. Tennessee running back Dylan Sampson is The Associated Press offensive player of the year in the Southeastern Conference and South Carolina defensive lineman Kyle Kennard is the top defensive player. Vanderbilt quarterback Diego Pavia was voted the top newcomer on Wednesday while the Gamecocks' Shane Beamer is coach of the year in voting by the panel of 17 media members who cover the league. Sampson led the SEC and set school records by rushing for 1,485 yards and 22 touchdowns. He is tied for third nationally in rushing touchdowns, recording the league's fifth-most in a season. Sampson was chosen on all but two ballots. Mississippi wide receiver Tre Harris and his quarterback, Jaxson Dart, each got a vote. Kennard led the SEC with 11-1/2 sacks and 15-1/2 tackles for loss. He also had 10 quarterback hurries and forced three fumbles. Beamer led the Gamecocks to just their fifth nine-win season, including a school-record four wins over Top 25 opponents. They've won their last six games and ended the regular season with a win over eventual ACC champion Clemson. South Carolina plays Illinois on Dec. 31 in the Citrus Bowl. Pavia helped lead Vandy to its first bowl game since 2018 after transferring from New Mexico State. He passed for 2,133 yards and 17 touchdowns with four interceptions. He ran for another 716 yards and six touchdowns, directing an upset of Alabama. AMES, Iowa — Matt Campbell, who led Iowa State to its first 10-win season and became the program's all-time leader in coaching victories, has agreed to an eight-year contract that would keep him with the Cyclones through 2032. University president Wendy Wintersteen and athletic director Jamie Pollard made the announcement Wednesday, four days after the Cyclones lost to Arizona State in the Big 12 championship game. “Given all the uncertainty currently facing college athletics, it was critical that we moved quickly to solidify the future of our football program,” Pollard said. “Matt is the perfect fit for Iowa State University and I am thrilled he wants to continue to lead our program. Leadership continuity is essential to any organization’s long-term success." The Cyclones won their first seven games for their best start since 1938 and are 10-3 heading into their game against Miami in the Pop Tarts Bowl in Orlando, Florida, on Dec. 28. BRIEFLY FLAG PLANT: Ohio Republican state Rep. Josh Williams said Wednesday on social media he's introducing a bill to make flag planting in sports a felony in the state. His proposal comes after the Nov. 30 fight at the Michigan-Ohio State rivalry football game when the Wolverines beat the Buckeyes 13-10 and then attempted to plant their flag at midfield. MALZAHN: Gus Malzahn, who resigned as UCF’s coach last month to become Mike Norvell’s offensive coordinator at Florida State, said he chose to return to his coaching roots rather than remain a head coach distracted by a myriad of responsibilities. Get local news delivered to your inbox!Best Contracting Services Breaks Ground on 264kW Microgrid and EV Charging Network in Gardena, CA7xm app login for android 。

The Game Awards 2024, held at the iconic Peacock Theater in Los Angeles on December 12th, was a night of surprises, stunning reveals, and emotional acceptance speeches. But amidst the glitz and glamour, one moment stood out: Astro Bot, the charming 3D platformer developed by Team Asobi, was crowned Game of the Year, beating out heavy hitters like Final Fantasy VII: Rebirth and Elden Ring: Shadow of the Erdtree. This unexpected victory sent shockwaves through the gaming community. While Astro Bot was critically acclaimed, many anticipated the award would go to a title with a larger scope and more mainstream appeal. However, the adorable robot’s triumph signifies a growing appreciation for innovative gameplay, heartfelt storytelling, and pure, unadulterated fun. A David Amongst Goliaths Astro Bot’s journey to Game of the Year was an underdog story in the making. Facing off against juggernauts like Final Fantasy VII: Rebirth, which led the nominations with seven nods, and the critically acclaimed Elden Ring: Shadow of the Erdtree, Astro Bot’s victory seemed like a long shot. Yet, the game’s unique blend of platforming mastery, VR integration, and sheer charm resonated with both players and critics alike. The game’s success can be attributed to several factors. Firstly, Astro Bot delivered a truly innovative platforming experience. By utilizing the PlayStation 5’s DualSense controller and VR capabilities, Team Asobi created a game that felt both fresh and familiar. The haptics, adaptive triggers, and immersive 3D environments brought a new level of depth and engagement to the genre. Secondly, Astro Bot’s undeniable charm won the hearts of players worldwide. The game’s protagonist, Astro, is an endearing character with a wide range of expressive animations. The vibrant and colorful world, filled with playful enemies and hidden secrets, further enhanced the game’s appeal. Finally, Astro Bot’s masterful level design provided a challenging yet rewarding experience. Each level was meticulously crafted, offering a perfect balance of platforming, puzzle-solving, and combat. The game’s difficulty curve was expertly tuned, ensuring that players of all skill levels could enjoy the adventure. A Triumph for Innovation and Heart Astro Bot’s Game of the Year win is a testament to the power of innovation and heart in video games. In an industry often dominated by sequels and established franchises, Astro Bot dared to be different. It took risks, embraced new technology, and delivered an experience that was both refreshing and nostalgic. The game’s victory also highlights the growing importance of VR in the gaming landscape. While VR gaming is still relatively niche, Astro Bot demonstrated the immense potential of the technology. By seamlessly integrating VR into its core gameplay, Team Asobi created an experience that was truly immersive and unforgettable. Moreover, Astro Bot’s success serves as a reminder that games can be more than just entertainment. They can be sources of joy, wonder, and emotional connection. Astro Bot’s charming world and heartwarming story resonated with players on a deep level, proving that games can have a profound impact on our lives. The Game Awards 2024: A Night of Surprises and Celebrations Beyond Astro Bot’s historic win, The Game Awards 2024 was a night filled with memorable moments. From stunning musical performances by Snoop Dogg and Twenty One Pilots to exciting game reveals and emotional acceptance speeches, the event was a celebration of the best that the gaming industry has to offer. Other notable winners included: The Game Awards also recognized the achievements of individuals who have made significant contributions to the gaming industry. This year’s Innovation Award went to Fallout (Amazon MGM Studios) for its groundbreaking work in adapting video game narratives to television. A Bright Future for Astro and Team Asobi Astro Bot’s Game of the Year win is a momentous achievement for Team Asobi and a testament to their dedication to creating innovative and joyful gaming experiences. This recognition is likely to propel the studio to new heights, and fans eagerly anticipate what they have in store for the future. Will we see a new Astro Bot adventure on the PlayStation 5? Will Team Asobi continue to push the boundaries of VR gaming? Only time will tell. But one thing is certain: Astro Bot’s triumph at The Game Awards 2024 has solidified its place as a modern classic and a shining example of the power of creativity and passion in video game development.

The US Open's first female tournament director will step down in 2025Jamey Helgeson: LIFE Mower County has launched Best Buddies Citizens Chapter: Building friendships, creating inclusionSusan Shelley: Politicians, read the Constitution

WALTHAM, Mass.--(BUSINESS WIRE)--Dec 13, 2024-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com . To participate in the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference code 9934051. A replay of the webcast will be available following the completion of the event. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com . Follow Viridian on LinkedIn and X . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “design,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical and clinical development of Viridian’s product candidates veligrotug (formerly VRDN-001), VRDN-003, VRDN-006 and VRDN-008; Viridian’s product candidates potentially being best-in-class; and the potential for Viridian’s product candidates to be developed in multiple autoimmune diseases. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to the potential utility, efficacy, potency, safety, clinical benefits, clinical response and convenience of Viridian’s product candidates and those risks set forth under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. View source version on businesswire.com : https://www.businesswire.com/news/home/20241213672239/en/ CONTACT: Anabel Chan, 617-458-8725 Vice President, Investor Relations & Communications IR@viridiantherapeutics.com Louisa Stone, 617-272-4604 Manager, Investor Relations IR@viridiantherapeutics.com KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH HEALTH TECHNOLOGY OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Viridian Therapeutics, Inc. Copyright Business Wire 2024. PUB: 12/13/2024 06:00 PM/DISC: 12/13/2024 06:03 PM http://www.businesswire.com/news/home/20241213672239/enBaptist Health Richmond campaign raises $7.9 million to expand hospital services

Ex-Colorado footballer Bloom dedicates time to fulfilling wishes for older adultsBoeing struggles to make best-selling plane again

North Carolina nearing deal with Bill Belichick: Ranking 15 NFL head-coaching candidates for 2025 cycle